

DISCLOSURE OF RELEVANT RELATIONSHIPS & CONFIDENTIALITY STATEMENTS

For NIA-AA Guidelines Workgroup

Confidential

DISCLOSURE OF RELEVANT RELATIONSHIPS

For each of the categories below, (1) please disclose relationships that cover the last 12 months and for anticipated activities in the coming 12 months as of approximately April 2016. If you have none, please write "none." Relationships apply to you and to spouse or dependent children. (2) For each relationship, please indicate whether it is a "**Significant (>\$1,000) Financial Interest**" Financial interests include but are not limited to salary, consulting and / or speaker fees, honoraria, research support, equity interests (e.g., stocks, stock options, or other ownership interests), and intellectual property rights (e.g., patents, copyrights and royalties from such rights).

1. Research funding (federal, foundation and corporate) relevant to the topic of Alzheimer's disease.

Self	Eli Lilly	Clinical Research Project Funding	Significant
Self	Janssen	Clinical Research Project Funding	Significant
Self	Foundation of Neurologic Diseases (FND)	Research Funding	Significant
Self	Fidelity	Research Funding	Significant
Self	Alzheimer's Association	Research Funding	Significant
Self	NIA	Research Grant Site Principal Investigator	Significant

2. Consulting to a for-profit company (paid and unpaid) relevant to the topic of Alzheimer's disease.

Self	Abbvie	Honorarium	Consulting	Significant (<10k)
Self	Biogen	Honorarium	Consulting	Significant (<10k)
Self	Genentech	Honorarium	Consulting	Significant (<10k)
Self	Bracket	Honorarium	Consulting	Significant (<10k)
Self	Roche	Honorarium	Consulting	Significant (<10k)
Self	Sanofi	Honorarium	Consulting	Significant (<10k)
Self	Lundbeck	Honorarium	Consulting	Significant (<10k)
Self	Eisai	Honorarium	Consulting	Significant (<10k)
Self	Otsuka	Honorarium	Consulting	Significant (<10k)
Self	Pfizer	Honorarium	Consulting	Significant (<10k)
Self	Merck	Honorarium	Consulting	Significant (<10k)

Dr. Sperling serves as Project Director for the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study, a Public Private Partnership with NIH and Eli Lilly, and the Longitudinal Evaluation of Neurodegeneration and Amyloid Risk (LEARN) Study, funded by the Alzheimer's Association. She serves as the academic Global Principal Investigator for the EARLY Study, funded by Janssen. She is also the Principal Investigator of the Ante-Amyloid Prevention of Alzheimer's Disease (A3) Study, funded by NIH, and a to be determined pharma partner. All of these trials are testing anti-amyloid treatments at the preclinical stage of AD.

Spouse	Lundbeck	Honorarium	Consulting	Significant (<10k)
Spouse	Piramal	Honorarium	Consulting	Significant (<10k)
Spouse	Siemens	Honorarium	Consulting	Significant (<10k)
Spouse	Novartis	Honorarium	Consulting	Significant (<10k)

Spouse	Abbvie	Honorarium	Consulting	Significant (<10k)
Spouse	Biogen	Honorarium	Consulting	Significant (<10k)
Spouse	Genentech	Honorarium	Consulting	Significant (<10k)

3. Ownership of property relevant to the topic of Alzheimer’s disease (patents filed or approved, licenses and other property shares) -- for each, please indicate whether you do or do not accept royalties.

None


4. Equity in companies whose work is relevant to the topic of Alzheimer’s disease

None

5. Employment in companies whose work is relevant to the topic of Alzheimer’s disease

Self	Brigham and Women’s Hospital	Employee	Significant
Spouse	Massachusetts General Hospital	Employee	Significant

I will immediately notify NIA-AA Workgroup leads if a change occurs in any of the above during the tenure of my responsibilities,



Name

Signature

08/24/17
Date